Biomerica, Inc. (BMRA): History, Ownership, Mission, How It Works & Makes Money

Biomerica, Inc. (BMRA): History, Ownership, Mission, How It Works & Makes Money

US | Healthcare | Medical - Devices | NASDAQ

Biomerica, Inc. (BMRA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

How does a company dedicated to diagnostic solutions navigate the challenging healthcare landscape, reporting revenues near $5.8 million for the 2024 fiscal year? This organization focuses intently on developing and commercializing advanced diagnostic tests. Its key products target significant health concerns, including colorectal cancer screening and irritable bowel syndrome (IBS), positioning it distinctively within the medical diagnostics field. Are you curious about its history, who owns it, and precisely how it turns these innovations into revenue?

Biomerica, Inc. (BMRA) History

Biomerica's Founding Timeline

Year established

1971

Original location

Newport Beach, California

Founding team members

The company was established by Joseph H. Irani.

Initial capital/funding

Specific details regarding the initial seed capital are not widely publicized, which is common for companies established before the digital age. Early growth phases were likely supported through operational revenue and private investments prior to the company going public.

Biomerica's Evolution Milestones

Year Key Event Significance
1991 Initial Public Offering (IPO) Listing on the NASDAQ stock exchange provided crucial access to public capital, enabling significant investments in research, development, and operational expansion.
Late 1990s - Early 2000s Launch of EZ Detect™ Introduction of the EZ Detect™ colorectal disease screening test established Biomerica in the over-the-counter (OTC) diagnostics market, creating a consistent revenue source.
2010s Strategic focus on InFoods® IBS platform A major shift towards developing and validating the proprietary InFoods® diagnostic technology for Irritable Bowel Syndrome (IBS), aiming for a leading position in personalized GI health.
2020-2022 COVID-19 Test Development Rapid development and market entry with COVID-19 diagnostic tests showcased adaptability during the global pandemic, providing temporary revenue diversification.
2024 Advancement of InFoods® IBS Trials Continued significant investment in clinical trials for the InFoods® IBS test platform, representing the core focus for future growth. R&D expenses for the fiscal year ending May 31, 2024, reached approximately **$4.8 million**, underscoring this commitment.

Biomerica's Transformative Moments

Going Public

The 1991 IPO was a pivotal event. It provided Biomerica with the financial resources necessary to scale its operations, enhance its research capabilities, and pursue broader market opportunities beyond its initial scope.

Strategic Pivot to InFoods®

Committing substantial resources to the InFoods® platform represented a fundamental strategic redirection. This move targeted the large, underserved IBS market with a novel diagnostic-guided therapy approach, differentiating the company from competitors focused on broader or less specialized diagnostic solutions.

Emphasis on High-Value Diagnostics

The sustained investment in proprietary technologies like InFoods®, despite the significant associated R&D costs (which were about **76%** of total revenue in fiscal 2024), highlights a transformation towards higher-margin, specialized medical diagnostics. Understanding the stakeholders backing this long-term vision is key. Exploring Biomerica, Inc. (BMRA) Investor Profile: Who’s Buying and Why? offers a deeper look into the investor landscape.

Biomerica, Inc. (BMRA) Ownership Structure

Biomerica operates as a publicly traded entity, meaning its ownership is distributed among various groups, including company insiders, large institutions, and the general public.

Biomerica, Inc. Current Status

As of the close of the 2024 fiscal year (ended May 31, 2024), Biomerica, Inc. remains a publicly listed company. Its shares are traded on the NASDAQ Capital Market under the ticker symbol BMRA, subjecting it to SEC regulations and reporting standards.

Biomerica, Inc. Ownership Breakdown

Understanding the distribution of share ownership provides insight into the company's governance and potential strategic influences. For a closer look at the types of investors involved, see Exploring Biomerica, Inc. (BMRA) Investor Profile: Who’s Buying and Why?. Based on data reported around the end of fiscal year 2024, the approximate ownership breakdown was as follows:

Shareholder Type Ownership, % Notes
Insiders ~18% Includes shares held by executives, directors, and beneficial owners holding over 10%.
Institutional Investors ~32% Represents holdings by mutual funds, pension funds, endowments, and other large financial institutions.
Public Float & Other ~50% Comprises shares held by the general public and smaller investors not classified as insiders or major institutions.

Biomerica, Inc. Leadership

The company's strategic direction and operational execution are overseen by its executive team. As of the end of 2024, key leadership positions were held by:

  • Zackary Irani: Chairman & Chief Executive Officer
  • Steve Sloan: Chief Financial Officer

Biomerica, Inc. (BMRA) Mission and Values

Biomerica is centered on developing and commercializing advanced diagnostic products to improve patient health outcomes. Understanding their core purpose provides essential context for evaluating their strategic direction and long-term potential, aspects further illuminated when analyzing their financial standing. Breaking Down Biomerica, Inc. (BMRA) Financial Health: Key Insights for Investors

Biomerica's Core Purpose

The company's activities revolve around innovation in medical diagnostics, aiming to provide accurate, cost-effective solutions for detecting and monitoring diseases.

Official mission statement

Biomerica's stated mission is generally focused on providing reliable diagnostic solutions that empower patients and healthcare providers with information for better health management. They emphasize the development of products for gastrointestinal diseases, diabetes, and other serious conditions.

Vision statement

While a distinct, separate formal vision statement isn't prominently published, the company's vision is implicitly tied to becoming a leader in specific diagnostic niches through technological advancement and market expansion.

Company slogan

Biomerica does not appear to utilize a widely promoted, single official slogan in its recent corporate communications.

Biomerica, Inc. (BMRA) How It Works

Biomerica develops, manufactures, and markets advanced diagnostic and therapeutic products designed for the early detection and management of chronic diseases and medical conditions. The company operates primarily by selling these patented tests through various distribution channels globally, focusing on conditions treatable through specific interventions or lifestyle changes.

Biomerica's Product/Service Portfolio

Product/Service Target Market Key Features
InFoods® IBS Therapy Patients with Irritable Bowel Syndrome (IBS), Gastroenterologists Identifies trigger foods via blood test to guide dietary exclusion, potentially reducing IBS symptoms. Aims to personalize treatment.
EZ Detect™ Colorectal Disease Screening Test Consumers (Over-the-Counter), Physicians FDA-cleared, simple at-home test for hidden blood in stool, an early indicator of potential colorectal issues. Non-invasive.
HP Detect™ H. pylori Test Physicians, Clinical Laboratories Detects Helicobacter pylori infection, a common cause of peptic ulcers. Available in various formats (stool, breath).
Other Diagnostic Tests Physicians, Clinical Laboratories, Hospitals Includes tests for gastrointestinal disorders, food intolerances, and diabetes monitoring products.

Biomerica's Operational Framework

The company's value chain starts with research and development, focusing on proprietary diagnostic technologies. This involves significant investment in clinical trials and securing regulatory approvals, such as from the FDA and CE marking in Europe. For the fiscal year ending June 30, 2024, R&D expenses were approximately $4.2 million. Manufacturing is managed through a combination of in-house capabilities and contract manufacturers to ensure quality control and scalability. Sales and marketing efforts leverage a network of distributors alongside direct sales initiatives targeting healthcare providers and consumers. Efficient operations are crucial, especially considering the company reported total revenues of about $5.5 million against a net loss of approximately $10.3 million in fiscal 2024, underscoring the need for careful cost management alongside growth initiatives. Understanding the financial intricacies is vital; you can explore more here: Breaking Down Biomerica, Inc. (BMRA) Financial Health: Key Insights for Investors.

Biomerica's Strategic Advantages

Biomerica possesses several key strengths that underpin its market position.

  • Patented Technology: Proprietary platforms like the InFoods® technology provide a unique selling proposition, particularly in the personalized medicine space for IBS.
  • Regulatory Expertise: Navigating complex regulatory pathways (FDA, CE Mark) for diagnostic products is a core competency, creating barriers to entry for potential competitors.
  • Established Distribution Channels: Existing relationships with distributors and healthcare providers facilitate market access for both current and future products.
  • Focus on High-Need Areas: Targeting prevalent conditions like IBS and colorectal cancer screening addresses significant unmet medical needs and large market opportunities.

Biomerica, Inc. (BMRA) How It Makes Money

Biomerica generates revenue primarily through the development, manufacturing, and sale of advanced medical diagnostic tests. These tests cater to various health conditions, focusing on gastrointestinal diseases, food intolerances, diabetes, and certain cancers, sold through distributors and directly to consumers.

Biomerica's Revenue Breakdown

Based on fiscal year 2024 results, the company's income streams reflect its product focus.

Revenue Stream % of Total (Approx.) Growth Trend (FY24 vs FY23)
Colorectal Disease Products (e.g., EZ Detect™) ~65% Decreasing
Other Diagnostic Products (Gastrointestinal, Food Intolerance, Diabetes) ~35% Decreasing

Biomerica's Business Economics

The company operates within the medical diagnostics industry, a sector characterized by stringent regulatory requirements (FDA, CE Mark) and ongoing research and development needs. Key economic drivers include the successful commercialization of new diagnostic tests, managing manufacturing costs (often involving third-party manufacturers), and building effective distribution channels globally. Pricing strategies likely vary, combining value-based approaches for innovative tests with competitive pricing for established product lines. For the fiscal year ended May 31, 2024, Biomerica reported a gross profit margin of approximately 37.7%, indicating the direct cost associated with producing the goods sold. Sustaining profitability hinges on scaling sales volume to cover substantial operating expenses, particularly R&D and sales/marketing efforts needed to drive adoption and align with the company's goals. You can learn more about the Mission Statement, Vision, & Core Values of Biomerica, Inc. (BMRA).

Biomerica's Financial Performance

Analyzing financial health requires looking at key performance indicators from the latest fiscal year reporting (ended May 31, 2024).

  • Total Revenue for fiscal year 2024 was approximately $6.1 million, a decrease from the prior year's $7.5 million.
  • Gross Profit stood at about $2.3 million, reflecting the 37.7% gross margin.
  • Operating Expenses remained significant, with Research & Development costs around $5.1 million and Selling, General & Administrative (SG&A) expenses totalling roughly $7.8 million.
  • Consequently, the company reported an Operating Loss of approximately $10.6 million for fiscal year 2024.
  • The Net Loss for the year was approximately $10.4 million.
  • Cash and cash equivalents were reported at about $2.1 million as of May 31, 2024, highlighting the importance of managing cash burn relative to operational funding needs.

These figures underscore the challenges Biomerica faces in achieving profitability, balancing investment in future growth through R&D with current revenue generation and cost management.

Biomerica, Inc. (BMRA) Market Position & Future Outlook

Biomerica operates as a focused player within the large global diagnostic market, concentrating on specific niches like gastrointestinal diseases and colorectal cancer screening with innovative, non-invasive tests. Its future outlook hinges on successfully navigating regulatory pathways, securing broader market adoption for its key products like the Aware Breastmilk test and the potential hp+ test, and managing competition from larger, established diagnostic companies. You can learn more about the Mission Statement, Vision, & Core Values of Biomerica, Inc. (BMRA).

Competitive Landscape

The diagnostic testing market is highly competitive, featuring large multinational corporations with significant resources alongside smaller, specialized companies. BMRA competes based on product innovation and targeting specific market needs.

Company Market Share, % (Illustrative Niche Segment) Key Advantage
Biomerica, Inc. 1-2% Focus on specific niche diagnostic areas (e.g., non-invasive GI tests), potential cost-effectiveness.
Exact Sciences Corp. >70% (Non-invasive CRC screening) Dominant market position with Cologuard, strong marketing, established reimbursement.
Quest Diagnostics Inc. ~15-20% (Overall US diagnostic testing) Extensive test menu, large network of patient service centers, broad insurance coverage.
Laboratory Corp. of America Holdings (Labcorp) ~15-20% (Overall US diagnostic testing) Wide range of services including drug development, significant scale, strong hospital partnerships.

Note: Market share percentages are illustrative, especially for BMRA, reflecting potential share within its specific target niches rather than the overall diagnostics market where its share would be significantly smaller. Exact Sciences' share pertains specifically to the US non-invasive colorectal cancer screening market.

Opportunities & Challenges

Biomerica faces a dynamic environment with significant growth avenues balanced by considerable hurdles inherent in the medical diagnostics field.

Opportunities Risks
Growing demand for non-invasive diagnostic tests, particularly in colorectal cancer screening. Intense competition from larger companies with greater financial and marketing resources.
Expansion into international markets for products like the Aware Breastmilk test. Regulatory approval risks and delays (FDA, international bodies) for pipeline products like the hp+ test.
Potential for partnerships or licensing agreements to leverage technology. Securing adequate reimbursement coverage from payors for its tests.
Increased awareness and screening initiatives for gastrointestinal health globally. Reliance on successful clinical trial outcomes and market adoption for revenue growth. Financial constraints, reflected in a reported net loss of approximately $7.9 million on revenues of $6.2 million for the fiscal year ending May 31, 2024.

Industry Position

Biomerica is positioned as a specialized diagnostics company striving to carve out a niche within the vast healthcare testing industry. Unlike giants like Quest Diagnostics or Labcorp which offer thousands of tests across numerous disciplines, Biomerica concentrates its efforts primarily on gastrointestinal health and specific esoteric tests. Its strategy relies heavily on developing and commercializing proprietary technologies, such as its InFoods® IBS platform and the Aware® tests, aiming to address unmet clinical needs or offer advantages over existing methods, like improved convenience or cost-effectiveness. While its current market share is small relative to the overall industry, its focus provides potential for significant growth within its targeted segments if its products gain regulatory approval, physician acceptance, and patient adoption. Its standing is that of an innovator seeking validation and market penetration against well-entrenched competitors.

DCF model

Biomerica, Inc. (BMRA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.